Evidence map›Paper›PMID 26544897›Full record

ArticleOncotarget2015

5-Fluorouracil-induced RNA stress engages a TRAIL-DISC-dependent apoptosis axis facilitated by p53.

Birce Akpinar, Ethiene V Bracht, Dorin Reijnders, Barbora Safarikova, Iva Jelinkova, Alf Grandien, Alena Hyrslova Vaculova, Boris Zhivotovsky, Magnus Olsson

Erratum issuedOpen access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Redox processes in the treatment of advanced skin cancers.Clinical & experimental metastasis · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Birce AkpinarDivision of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Ethiene V BrachtDivision of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Dorin ReijndersDivision of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Barbora SafarikovaDepartment of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Brno, Czech Republic.
Iva JelinkovaDepartment of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Brno, Czech Republic.
Alf GrandienDepartment of Medicine, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital-Huddinge, Stockholm, Sweden.
Alena Hyrslova VaculovaDivision of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Boris ZhivotovskyDivision of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Magnus OlssonDivision of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet · SECzech Academy of Sciences · CZCzech Academy of Sciences, Institute of Biophysics · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite recent advances in targeted therapeutics, administration of 5-fluorouracil (5-FU) remains a common clinical strategy for post-surgical treatment of solid tumors. Although it has been proposed that RNA metabolism is disturbed by 5-FU treatment, the key cytotoxic response is believed to be enzymatic inhibition of thymidylate synthase resulting in nucleotide pool disproportions. An operating p53 tumor suppressor signaling network is in many cases essential for the efficiency of chemotherapy, and malfunctions within this system remain a clinical obstacle. Since the fate of chemotherapy-insensitive tumor cells is rarely described, we performed a comparative analysis of 5-FU toxicity in p53-deficient cells and conclude that p53 acts as a facilitator rather than a gatekeeper of cell death. Although p53 can act as a regulator of several cellular stress responses, no rerouting of cell death mode was observed in absence of the tumor suppressor. Thus, the final death outcome of 5-FU-treated p53-/- cells is demonstrated to be caspase-dependent, but due to a slow pace, accumulation of mitochondrial reactive oxygen species contributes to necrotic characteristics. The oligomerization status of the p53 target gene DR5 is determined as a significant limiting factor for the initiation of caspase activity in an intracellular TRAIL-dependent manner. Using several experimental approaches, we further conclude that RNA-rather than DNA-related stress follows by caspase activation irrespectively of p53 status. A distinct 5-FU-induced stress mechanism is thereby functionally connected to a successive and discrete cell death signaling pathway. Finally, we provide evidence that silencing of PARP-1 function may be an approach to specifically target p53-deficient cells in 5-FU combinatorial treatment strategies. Together, our results disclose details of impaired cell death signaling engaged as a consequence of 5-FU chemotherapy. Obtained data will contribute to the comprehension of factors restraining 5-FU efficiency, and by excluding DNA as the main stress target in some cell types they propose alternatives to currently used and suggested synergistic treatment regimens.

Indexed as

Antimetabolites, AntineoplasticApoptosisCell Line, TumorFluorescent Antibody TechniqueFluorouracilHumansImmunoblottingImmunoprecipitationMicroscopy, Electron, TransmissionPolymerase Chain ReactionRNASignal TransductionTNF-Related Apoptosis-Inducing LigandTransduction, GeneticTumor Suppressor Protein p53Antimetabolites, AntineoplasticFluorouracilRNATNF-Related Apoptosis-Inducing LigandTP53 protein, humanTumor Suppressor Protein p535-fluorouracilapoptosiscolon cancernecrosisp53

Identifiers

PMID26544897
PMCPMC4791259
OpenAlexW2156899841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.